Sugi Predict

Sugi Predict / Targets / CCR4

CCR4

C-C chemokine receptor type 4 · P51679 · CCR4 on Sugi Atlas →

32,253 patent compounds predicted against CCR4, 17,130 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL18861 SCHEMBL18861 1.00 20/20
SCHEMBL27059 SCHEMBL27059 1.00 20/20
SCHEMBL186214 SCHEMBL186214 1.00 20/20
SCHEMBL186736 SCHEMBL186736 1.00 20/20
SCHEMBL250494 SCHEMBL250494 1.00 20/20
SCHEMBL355885 SCHEMBL355885 1.00 20/20
SCHEMBL355893 SCHEMBL355893 1.00 20/20
SCHEMBL356133 SCHEMBL356133 1.00 20/20
SCHEMBL356170 SCHEMBL356170 1.00 20/20
SCHEMBL356525 SCHEMBL356525 1.00 20/20
SCHEMBL356726 SCHEMBL356726 1.00 20/20
SCHEMBL356848 SCHEMBL356848 1.00 20/20
SCHEMBL356927 SCHEMBL356927 1.00 20/20
SCHEMBL356962 SCHEMBL356962 1.00 20/20
SCHEMBL357053 SCHEMBL357053 1.00 20/20
SCHEMBL357121 SCHEMBL357121 1.00 20/20
SCHEMBL357509 SCHEMBL357509 1.00 20/20
SCHEMBL357566 SCHEMBL357566 1.00 20/20
SCHEMBL357718 SCHEMBL357718 1.00 20/20
SCHEMBL357794 SCHEMBL357794 1.00 20/20

Clinical trials — most relevant to CCR4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized) PHASE3UNKNOWN
Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia PHASE3SUSPENDED
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment PHASE2UNKNOWN
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) PHASE2COMPLETED
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver PHASE2COMPLETED
Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma PHASE1/PHASE2COMPLETED
Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients PHASE1/PHASE2COMPLETED
Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) PHASE1/PHASE2ACTIVE_NOT_RECRUITING
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) PHASE1RECRUITING
Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL PHASE1COMPLETED
GSK2239633 FTIH Study PHASE1COMPLETED
U69-CART-Cells For R/R T-ALL PHASE1RECRUITING
Placebo-controlled Assessment of the Effect of a Food Supplement on Skin Protection After Exposure to UV Radiation PHASE1COMPLETED
X4P-001 and Pembrolizumab in Patients With Advanced Melanoma PHASE1COMPLETED
Phenotyping Circulating and Lung Resident Eosinophils in Severe Asthma (P-CLESA) nanUNKNOWN
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia nanUNKNOWN
Evaluation of CCR6 Gene Expression and Circulating CCL20 Levels as Potential Biomarkers in Rheumatoid Arthritis nanNOT_YET_RECRUITING
Genetic Polymorphism Associated With Coronary Heart Disease Susceptibility and Variability of Clopidogrel Response nanACTIVE_NOT_RECRUITING
Circular RNA and Chemerin in Breast Cancer Patient nanUNKNOWN
IL-11 in the Development of Multiple Sclerosis nanUNKNOWN
Lung-Resident Memory Th2 Cells in Asthma nanACTIVE_NOT_RECRUITING
The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma nanUNKNOWN
The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma nanUNKNOWN
The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis nanUNKNOWN
Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio) nanCOMPLETED
Inflammatory Biomarkers in Psychogenic Non-epileptic Seizure nanUNKNOWN
Comparative Study Between Alzheimer's and Multi-infarct Dementia nanUNKNOWN
Value of Various Chemokines in the Detection and Follow up of RCC nanUNKNOWN
Inflammatory Biomarkers in Seizure nanUNKNOWN
Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CCR4 binder may also engage these)

ProteinNameSimilarity
CCR8 C-C chemokine receptor type 8 1.000 landscape →
Q95ND1 — 1.000 Q95ND1 →
P61815 — 0.999 P61815 →
Q9TV48 — 0.997 Q9TV48 →
Q95NE8 — 0.997 Q95NE8 →
P61755 — 0.997 P61755 →
P56439 — 0.997 P56439 →
P51680 — 0.996 P51680 →
O97881 — 0.995 O97881 →
CCR7 C-C chemokine receptor type 7 0.993 landscape →
Q95NC3 — 0.993 Q95NC3 →
Q2KTE1 — 0.993 Q2KTE1 →
Q5MD62 — 0.993 Q5MD62 →
O97962 — 0.992 O97962 →
O97880 — 0.991 O97880 →
P47774 — 0.991 P47774 →
Q95NC1 — 0.990 Q95NC1 →
P61757 — 0.990 P61757 →
O97879 — 0.990 O97879 →
Q8MJW8 — 0.990 Q8MJW8 →
O62743 — 0.990 O62743 →
O97882 — 0.990 O97882 →
CCR1 C-C chemokine receptor type 1 0.990 landscape →
O97883 — 0.990 O97883 →
Q95ND2 — 0.989 Q95ND2 →
CXCR2 C-X-C chemokine receptor type 2 0.989 landscape →
Q2YEG0 — 0.989 Q2YEG0 →
Q95ND0 — 0.989 Q95ND0 →
Q9EQ16 — 0.989 Q9EQ16 →
P35344 — 0.988 P35344 →